» Articles » PMID: 22433122

Hormone Replacement Therapy and Physical Function in Healthy Older Men. Time to Talk Hormones?

Overview
Journal Endocr Rev
Specialty Endocrinology
Date 2012 Mar 22
PMID 22433122
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Improving physical function and mobility in a continuously expanding elderly population emerges as a high priority of medicine today. Muscle mass, strength/power, and maximal exercise capacity are major determinants of physical function, and all decline with aging. This contributes to the incidence of frailty and disability observed in older men. Furthermore, it facilitates the accumulation of body fat and development of insulin resistance. Muscle adaptation to exercise is strongly influenced by anabolic endocrine hormones and local load-sensitive autocrine/paracrine growth factors. GH, IGF-I, and testosterone (T) are directly involved in muscle adaptation to exercise because they promote muscle protein synthesis, whereas T and locally expressed IGF-I have been reported to activate muscle stem cells. Although exercise programs improve physical function, in the long-term most older men fail to comply. The GH/IGF-I axis and T levels decline markedly with aging, whereas accumulating evidence supports their indispensable role in maintaining physical function integrity. Several studies have reported that the administration of T improves lean body mass and maximal voluntary strength in healthy older men. On the other hand, most studies have shown that administration of GH alone failed to improve muscle strength despite amelioration of the detrimental somatic changes of aging. Both GH and T are anabolic agents that promote muscle protein synthesis and hypertrophy but work through separate mechanisms, and the combined administration of GH and T, albeit in only a few studies, has resulted in greater efficacy than either hormone alone. Although it is clear that this combined approach is effective, this review concludes that further studies are needed to assess the long-term efficacy and safety of combined hormone replacement therapy in older men before the medical rationale of prescribing hormone replacement therapy for combating the sarcopenia of aging can be established.

Citing Articles

Ubiquitin-proteasome pathway in skeletal muscle atrophy.

Pang X, Zhang P, Chen X, Liu W Front Physiol. 2023; 14:1289537.

PMID: 38046952 PMC: 10690626. DOI: 10.3389/fphys.2023.1289537.


Clinical-grade human umbilical cord-derived mesenchymal stem cells improved skeletal muscle dysfunction in age-associated sarcopenia mice.

Wang C, Zhao B, Zhai J, Wang A, Cao N, Liao T Cell Death Dis. 2023; 14(5):321.

PMID: 37173309 PMC: 10182022. DOI: 10.1038/s41419-023-05843-8.


Prevalence of Sarcopenic Obesity in Various Comorbidities, Diagnostic Markers, and Therapeutic Approaches: A Review.

Kumari M, Khanna A Ann Geriatr Med Res. 2022; 26(4):296-308.

PMID: 36397294 PMC: 9830070. DOI: 10.4235/agmr.22.0081.


Effects of L. on Sport and Health Biomarkers in Physically Active Adult Males: A Systematic Review.

Fernandez-Lazaro D, Fernandez-Lazaro C, Seco-Calvo J, Garrosa E, Adams D, Mielgo-Ayuso J Int J Environ Res Public Health. 2022; 19(15).

PMID: 35954909 PMC: 9368143. DOI: 10.3390/ijerph19159533.


Human umbilical cord-derived mesenchymal stromal cells ameliorate aging-associated skeletal muscle atrophy and dysfunction by modulating apoptosis and mitochondrial damage in SAMP10 mice.

Piao L, Huang Z, Inoue A, Kuzuya M, Cheng X Stem Cell Res Ther. 2022; 13(1):226.

PMID: 35659361 PMC: 9166592. DOI: 10.1186/s13287-022-02895-z.


References
1.
Simon D, Charles M, Nahoul K, Orssaud G, Kremski J, Hully V . Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab. 1997; 82(2):682-5. DOI: 10.1210/jcem.82.2.3766. View

2.
Cuneo R, Salomon F, Wiles C, Round J, Jones D, Hesp R . Histology of skeletal muscle in adults with GH deficiency: comparison with normal muscle and response to GH treatment. Horm Res. 1992; 37(1-2):23-8. DOI: 10.1159/000182276. View

3.
Corpas E, Harman S, Blackman M . Human growth hormone and human aging. Endocr Rev. 1993; 14(1):20-39. DOI: 10.1210/edrv-14-1-20. View

4.
Bhasin S, Singh A, Mac R, Carter B, Lee M, Cunningham G . Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl. 2003; 24(3):299-311. DOI: 10.1002/j.1939-4640.2003.tb02676.x. View

5.
Giannoulis M, Jackson N, Shojaee-Moradie F, Nair K, Sonksen P, Martin F . The effects of growth hormone and/or testosterone on whole body protein kinetics and skeletal muscle gene expression in healthy elderly men: a randomized controlled trial. J Clin Endocrinol Metab. 2008; 93(8):3066-74. PMC: 2515076. DOI: 10.1210/jc.2007-2695. View